Non-ownership Filings
| Saphnelo met primary endpoint in TULIP-SC | Sep. 17, 2025 |
| Update on RESOLUTE Phase III trial | Sep. 17, 2025 |
| Total Voting Rights | Sep. 01, 2025 |
| Total Voting Rights | Aug. 01, 2025 |
| H1 and Q2 2025 results | Jul. 29, 2025 |
| Gefurulimab nanobody met Phase III endpoints | Jul. 24, 2025 |
| AstraZeneca plans to invest $50bn in the US | Jul. 22, 2025 |
Ownership Update Filings
| Holding(s) in Company | Aug. 28, 2025 |
| Holding(s) in Company | Aug. 26, 2025 |
| Holding(s) in Company | Aug. 21, 2025 |
| Director/PDMR Shareholding | Aug. 18, 2025 |
| Holding(s) in Company | Aug. 15, 2025 |
| Holding(s) in Company | Aug. 12, 2025 |
| Director/PDMR Shareholding | Jun. 12, 2025 |